Discuss Chonluten on glp1chat
Join the forum to discuss research with other members.
At a glance
Chonluten is a short peptide studied in respiratory-tissue and immune-cell experiments. Researchers look for changes in cell activity and inflammation signals rather than a single established effect on breathing.
The proposed idea is to change how cells in airway tissue and the immune system respond to stress or inflammatory signals. Experiments can measure those cell messages and tissue changes directly. They do not yet show a predictable improvement in breathing for a person. That is why the biology here is better described as early tissue research than as an established lung treatment.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source includes experimental respiratory-tissue and immune-cell context. Such findings should not be presented as proof of improved breathing or treatment of lung disease.[1][5]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Chonluten.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 20 mg · 1 source tables
Standard / Gradual Approach (3 mL = 6.67 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 250 mcg (0.25 mg) | 3.75 units (0.0375 mL) |
| Weeks 3–4 | 500 mcg (0.5 mg) | 7.5 units (0.075 mL) |
| Weeks 5–6 | 1,000 mcg (1 mg) | 15 units (0.15 mL) |
| Weeks 7–8 | 1,500 mcg (1.5 mg) | 22.5 units (0.225 mL) |
| Weeks 9–10 | 2,000 mcg (2 mg) | 30 units (0.30 mL) |
| Weeks 11–12 | 3,000 mcg (3 mg) | 45 units (0.45 mL) |
| Weeks 13–14 | 4,000 mcg (4 mg) | 60 units (0.60 mL) |
| Weeks 15–16 | 4,000 mcg (4 mg) | 60 units (0.60 mL) |
Frequency: Inject once daily subcutaneously. For ≤10‑unit (≤0.10 mL) administrations during Weeks 1–4, consider 30‑ or 50‑unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Support bronchopulmonary tissue function and modulate inflammatory pathways[1].
- Schedule: Daily subcutaneous injections for 8–16 weeks with gradual titration.
- Dose Range: 250–4,000 mcg daily with incremental increases every 1–2 weeks.
- Reconstitution: 3.0 mL per 20 mg vial (6.67 mg/mL) for accurate unit measurements.
- Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 250 mcg daily; increase by 250–500 mcg every 1–2 weeks as tolerated.
- Target: Up to 4,000 mcg daily by Weeks 13–16.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–16 weeks; shorter durations (8–12 weeks) acceptable.
- Timing: Any consistent time; rotate injection sites.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality[3].
- Lyophilized (short‑term): Refrigerate at 4 °C (39.2 °F) in dry, dark conditions.
- Lyophilized (long‑term): Store at −20 °C (−4 °F) or colder; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within days to weeks and avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[4][7].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45° into subcutaneous tissue using a 25–27 gauge, ⅝‑inch needle[4].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[4].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[8].
Materials & quantity planning
Source materials checklist · 20 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (Chonluten, 20 mg each):
- 8 weeks ≈ 3 vials (45.5 mg total)
- 12 weeks ≈ 6 vials (115.5 mg total)
- 16 weeks ≈ 12 vials (227.5 mg total)
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 12 weeks (6 vials): 18 mL → 2 × 10 mL bottles
- 16 weeks (12 vials): 36 mL → 4 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 20 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 03
Source document
Sigma-Aldrich — Peptide Handling Guide (storage, reconstitution, and stability recommendations) (opens in a new tab)www.sigmaaldrich.com
Back to overview ↑ - 04
Public health resource
CDC (Subcut Injection PDF) — You Call the Shots: Subcutaneous Injection Technique (opens in a new tab)www.cdc.gov
Back to overview ↑ - 06
Public health resource
CDC — Preventing Unsafe Injection Practices (clinical safety guidance) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 08
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Research publication
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.